In recent years, fibroblast activation
protein (FAP) has emerged
as an important target for the diagnosis and therapy of various tumors
due to its high expression on the cell surface of cancer-associated
fibroblasts, which are the major components of the tumor stroma. In
this study, we synthesized and evaluated 18F-labeled FAP
inhibitors (FAPIs) for FAP imaging. Two silicon fluoride acceptor
(SiFA)-conjugated FAPIs were synthesized: one containing a γ-carboxy-l-glutamic acid (Gla) residue (1) and another containing
two Gla residues (2). Both ligands exhibited high binding
affinities for FAP. 18F/19F exchange reactions
on both ligands were performed in the presence of 2% water. This resulted
in the formation of radioligands [18F]1 and
[18F]2 in high radiochemical yields. Radioligand
[18F]2, with a more favorable partition coefficient,
was selected for the U87MG cell binding study, and the results showed
FAP-specific binding of the radioligand to the cells. An ex
vivo biodistribution study in U87MG tumor-bearing mice 60
min after injection demonstrated a 5.8-fold higher tumor accumulation
of [18F]2 than that of [18F]1. Furthermore, PET and ex vivo biodistribution
studies of [18F]2 in U87MG tumor-bearing mice
showed high and persistent tumor uptake over time, which was significantly
blocked by the preinjection of FAPI-04. Our results indicate that
[18F]SiFA-(Gla)2-conjugated FAPI ([18F]2) has the potential for FAP imaging.